Patents by Inventor Daniel Afar

Daniel Afar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080124332
    Abstract: Compositions and methods for treating MM are provided herein.
    Type: Application
    Filed: August 7, 2007
    Publication date: May 29, 2008
    Applicant: PDL BIOPHARMA, INC.
    Inventor: Daniel AFAR
  • Publication number: 20080095768
    Abstract: Methods for treating MM using anti-CS1 antibodies are provided herein.
    Type: Application
    Filed: August 7, 2007
    Publication date: April 24, 2008
    Applicants: PDL BIOPHARMA, INC., UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCE
    Inventors: Daniel AFAR, Frits VAN RHEE
  • Publication number: 20080044840
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Application
    Filed: August 10, 2007
    Publication date: February 21, 2008
    Applicant: PDL BIOPHARMA, INC.
    Inventors: Vinay BHASKAR, Agustin DE LA CALLE, Debbie LAW, Ingrid CARAS, Vanitha RAMAKRISHNAN, Richard MURRAY, Daniel AFAR, David POWERS
  • Publication number: 20080019971
    Abstract: Described is a gene and its encoded secreted tumor antigen, termed 36P6D5, and to diagnostic and therapeutic methods and compositions useful in the management of various cancers which express 36P6D5, particularly including cancers of the bladder, kidney, prostate, breast, colon, ovary and pancreas.
    Type: Application
    Filed: May 24, 2007
    Publication date: January 24, 2008
    Inventors: Arthur Raitano, Aya Jakobovits, Mary Faris, Daniel Afar, Rene Hubert, Steve Mitchell
  • Publication number: 20070275437
    Abstract: A novel gene (designated PHOR-1) that is highly over-expressed in prostate and other cancers and its encoded protein are described. PHOR-1 is a G protein-coupled receptor with homology to receptors involved in olfaction. PHOR-1 in normal human tissues is restricted to prostate, and this gene is highly over-expressed in prostate cancer as well as in cancers of the kidney, uterus, cervix, stomach and rectum. Consequently, PHOR-1 provides a diagnostic and/or therapeutic target for prostate cancer.
    Type: Application
    Filed: November 16, 2004
    Publication date: November 29, 2007
    Inventors: Arthur Raitano, Daniel Afar, Aya Jakobovits, Mary Faris, Rene Hubert, Steve Mitchell, Douglas Saffran
  • Publication number: 20070270575
    Abstract: A novel gene (designated 101P3A11 or PHOR-1) and its encoded protein, and variants thereof, are described wherein 101P3A11 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 101P3A11 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 101P3A11 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 101P3A11 can be used in active or passive immunization.
    Type: Application
    Filed: May 21, 2007
    Publication date: November 22, 2007
    Applicant: AGENSYS, INC.
    Inventors: Aya Jakobovits, Mary Faris, Daniel Afar, Douglas Saffran, Rene Hubert, Mary Faris, Pia Challita-Eid
  • Patent number: 7288248
    Abstract: Described herein are methods and compositions that can be used for diagnosis and treatment of cancer.
    Type: Grant
    Filed: March 7, 2003
    Date of Patent: October 30, 2007
    Assignee: PDL Biopharma, Inc.
    Inventors: Vinay Bhaskar, Agustin de la Calle, Debbie Law, Ingrid Caras, Vanitha Ramakrishnan, Richard Murray, Daniel Afar, David Powers
  • Publication number: 20070161016
    Abstract: Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein are methods that can be used to identify modulators of prostate cancer.
    Type: Application
    Filed: November 30, 2006
    Publication date: July 12, 2007
    Inventors: Daniel Afar, David Mack, David Agus
  • Publication number: 20070148089
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Application
    Filed: October 3, 2006
    Publication date: June 28, 2007
    Inventors: Rene Hubert, Arthur Raitano, Douglas Saffran, Daniel Afar, Steven Mitchell, Mary Faris, Aya Jakobovits
  • Publication number: 20070134253
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Application
    Filed: December 29, 2006
    Publication date: June 14, 2007
    Inventors: Daniel Afar, Rene Hubert, Atthur Raitano, Douglas Saffran, Stephen Mitchell
  • Publication number: 20070104720
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (SIX Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N— and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Application
    Filed: October 12, 2006
    Publication date: May 10, 2007
    Inventors: Daniel Afar, Rene Hubert, Kahan Leong, Arthur Raitano, Douglas Saffran, Stephen Mitchell
  • Publication number: 20070098729
    Abstract: Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigen of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops.
    Type: Application
    Filed: October 10, 2006
    Publication date: May 3, 2007
    Inventors: Daniel Afar, Rene Hubert, Arthur Raitano, Douglas Saffran, Stephen Mitchell
  • Publication number: 20070099197
    Abstract: The present invention applies classical survival analysis to genome-wide gene expression profiles of prostate cancers and preoperative prostate-specific antigen levels from prostate cancer patient, to identify prognostic markers of disease relapse that provide additional predictive value relative to prostate-specific antigen concentration. The present invention provides a method of determining prognosis of prostate cancer and predicting prostate cancer outcome of a patient. The method comprises the steps of first establishing the threshold value of at least one prognostic gene of prostate cancer. Then, the amount of the prognostic gene from a prostate tissue of a prostate cancer patient is determined. The amount of the prognostic gene present in that patient is compared with the established threshold value of the prognostic gene, whereby the prognostic outcome of the patient is determined.
    Type: Application
    Filed: February 28, 2006
    Publication date: May 3, 2007
    Inventors: Daniel Afar, Susan Henshall, Jordan Hiller, David Mack, Robert Sutherland
  • Publication number: 20070092918
    Abstract: A novel gene (designated PC-LECTIN) that is highly overexpressed in prostate cancer and its encoded protein is described. PC-LECTIN in normal human tissues is restricted to testis, but is highly expressed in prostate cancer. Consequently, PC-LECTIN provides a diagnostic and/or therapeutic target for prostate cancer.
    Type: Application
    Filed: October 10, 2006
    Publication date: April 26, 2007
    Inventors: Daniel Afar, Rene Hubert, Aya Jakobovits, Arthur Raitano
  • Publication number: 20070059748
    Abstract: Described herein are genes whose expression are up-regulated or down-regulated in specific cancers. Related methods and compositions that can be used for diagnosis and treatment of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.
    Type: Application
    Filed: September 6, 2006
    Publication date: March 15, 2007
    Applicant: PDL BIOPHARMA, INC.
    Inventors: Daniel Afar, Natasha Aziz, Kurt Gish, Peter Hevezi, David Mack, Keith Wilson, Albert Zlotnik
  • Publication number: 20070054363
    Abstract: A novel gene (designated 84P2A9) and its encoded protein is described. While 84P2A9 exhibits prostate and testis specific expression in normal adult tissue, it is aberrantly expressed multiple cancers including prostate, testis, kidney, brain, bone, skin, ovarian, breast, pancreas, colon, lymphocytic and lung cancers. Consequently, 84P2A9 provides a diagnostic and/or therapeutic target for cancers, and the 84P2A9 gene or fragment thereof, or its encoded protein or a fragment thereof used to elicit an immune response.
    Type: Application
    Filed: November 7, 2006
    Publication date: March 8, 2007
    Applicant: AGENSYS, INC.
    Inventors: Aya Jakobovits, Daniel Afar, Pia Challita-Eid, Elana Levin, Steve Mitchell, Rene Hubert
  • Publication number: 20070048299
    Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
    Type: Application
    Filed: June 17, 2005
    Publication date: March 1, 2007
    Applicant: AGENSYS, INC.
    Inventors: Aya Jakobovits, Pia Challita-Eid, Mary Faris, Wangmao Ge, Rene Hubert, Karen Morrison, Robert Morrison, Arthur Raitano, Daniel Afar
  • Publication number: 20070048283
    Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
    Type: Application
    Filed: June 15, 2005
    Publication date: March 1, 2007
    Applicant: AGENSYS, INC.
    Inventors: Aya Jakobovits, Pia Challita-Eid, Mary Faris, Wangmao Ge, Rene Hubert, Karen Morrison, Robert Morrison, Arthur Raitano, Daniel Afar
  • Publication number: 20070041968
    Abstract: Novel genes designated and set forth in FIG. 2 and their respective encoded proteins, and variants thereof, are described wherein a gene of the invention exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers such as those listed in Table I. Consequently, of gene products of a gene of FIG. 2 provide diagnostic, prognostic, prophylactic and/or therapeutic targets for cancer. A gene of FIG. 2 or fragment thereof, its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with a gene product of FIG. 2 can be used in active or passive immunization.
    Type: Application
    Filed: June 17, 2005
    Publication date: February 22, 2007
    Applicant: AGENSYS, INC.
    Inventors: Aya Jakobovits, Pia Challita-Eid, Mary Faris, Wangmao Ge, Rene Hubert, Karen Morrison, Robert Morrison, Arthur Raitano, Daniel Afar
  • Publication number: 20070042360
    Abstract: Described herein are genes whose expression are up-regulated or down-regulated in specific cancers. Related methods and compositions that can be used for diagnosis and treatment of those cancers are disclosed. Also described herein are methods that can be used to identify modulators of selected cancers.
    Type: Application
    Filed: September 17, 2002
    Publication date: February 22, 2007
    Applicant: Eos Biotechnology, Inc.
    Inventors: Daniel Afar, Natasha Aziz, Kurt Gish, Peter Hevezi, David Mack, Keith Wilson, Albert Zlotnik